HCV direct‐acting antiviral agents: the best interferon‐free combinations
Open Access
- 23 December 2013
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 34 (s1), 69-78
- https://doi.org/10.1111/liv.12423
Abstract
For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct‐acting antivirals (DAA) showing high potency, favourable tolerability profile, higher barrier to resistance, shortened treatment duration, all oral regimen, pan‐genotypic, fewer drug interactions and reduced pill burden. By 2014, several DAAs are anticipated to complete successful phase III trials and will be commercially available. Initially, a wave of IFN‐based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1. In the near future, combination of antiviral agents with additive potency that lack cross‐resistance with good safety profile will likely be the new recommended regimens, making HCV, the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN or ribavirin. The aim of this review was to summarize the results obtained from recent DAA combination studies without IFN.Keywords
Funding Information
- CFAR
- NIH (2P30AI-050409)
- Department of Veterans Affairs
This publication has 31 references indexed in Scilit:
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- The NS5A Replication Complex Inhibitors: Difference Makers?Clinics in Liver Disease, 2011
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 2010
- Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirinHepatology, 2009
- GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796Antimicrobial Agents and Chemotherapy, 2009
- Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CGut, 2007
- BILN 2061: a major step toward new therapeutic strategies in hepatitis CJournal of Hepatology, 2004
- Fibrosis and disease progression in hepatitis CHepatology, 2002
- Fibrosis and disease progression in hepatitis CHepatology, 2002
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989